Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
stocks
Tesla: Board announces new pay package for CEO Elon Musk
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,021.70 | 99.70 | 1.12% |
CAC 40 | 7,632.01 | 85.85 | 1.14% |
DAX 40 | 23,757.69 | 331.72 | 1.42% |
Dow JONES (US) | 44,173.64 | 585.06 | 1.34% |
FTSE 100 | 9,128.30 | 59.72 | 0.66% |
HKSE | 24,774.51 | 41.06 | 0.17% |
NASDAQ | 21,053.58 | 403.45 | 1.95% |
Nikkei 225 | 40,607.38 | 316.68 | 0.79% |
NZX 50 Index | 12,838.27 | 154.23 | 1.22% |
S&P 500 | 6,329.94 | 91.93 | 1.47% |
S&P/ASX 200 | 8,763.10 | 99.40 | 1.15% |
SSE Composite Index | 3,602.13 | 18.82 | 0.53% |